7Genazzani AR. Controversial issues in climacteric medcine (I)cardiovascular disease and hormone replacementtherapy. International Menopause Society Expert Workshop, 13 ~ 16October2000, Royal Society of Medcine, London, UK. Maturitas,2001~ 38:263.
8Van BaalWM, Smolders RG, Van derMoorenMJ, et al. Hormonereplacement therapy and plasma homocysteine levels. ObstetGynecol, 1999; 47 485.
10Prestwood KM, PilbeamCC, Burleson JA, et al. The short-termeffects of conjugated estegen on bone turnover in older women. JClin Endocrinol Metab, 1994; 97:366.
二级参考文献18
1杨藻宸，医用药理学（第3版），1994年，713页
2葛秦生，生殖医学杂志，1993年，2卷，195页
3程国钧，中华妇产科杂志，1993年，28卷，534页
4Christiansen C.Hormone replacement therapy and osteoporosis[].Maturitas.1996
5Christensen MS,Hagen C,Christiansen C,et al.Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women:placebo-controlled trial of its gynecologic and metabolic actions[].American Journal of Obstetrics and Gynecology.1982
6Mizunuma H,Okano H,Soda M,et al.Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study[].Maturitas.1997
7Felson DT,Zhang Y,Hannan MT,et al.The effect of postmenopausal estrogen therapy on bone densityn in elderly women[].The New England Journal of Medicine.1993
8Prestwood KM,Pilbeam CC,Burleson JA,et al.The short-term effects of conjugated esteogen on bone turnover in older women[].The Journal of Clinical Endocrinology.1994
9Paganini-Hill A.Hormone replacement therapy and stroke: risk,protection or no effect[].Maturitas.2001
10Shlipak MG,Simon JA,Vittinghoff E,et al.Estrogen and progestin,lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause[].The Journal of The American Medical Association.2000
